Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Lithocholic Acid Kills Cancer, Spares Healthy Cells

By LabMedica International staff writers
Posted on 19 Jan 2012
Lithocholic acid (LCA), naturally generated in the liver during digestion, has been seriously underestimated because new research has revealed that LCA can kill several kinds of cancer cells, such as those found in breast cancer and various brain tumors.

The researchers, led by Concordia University (Austin, TX, USA), included scientists from McGill University (Montreal, Canada) and the Jewish General Hospital’s Lady Davis Institute (Montreal, Canada), as well as the University of Saskatchewan (Saskatoon, Canada). More...
The study’s findings were published October 2011 in the journal Oncotarget.

Earlier research from the same investigators demonstrated LCA also extends the lifespan of aging yeast. This time, the team found LCA to be very selective in killing cancer cells while leaving normal cells unscathed. This could translate into a great improvement over the indiscriminant all-cell damaging drugs used in chemotherapy.

“LCA doesn’t just kill individual cancer cells. It could also prevent the entire tumor from growing,” stated senior author Vladimir Titorenko, a professor in the department of biology and Concordia University research chair in genomics, cell biology, and aging.

Moreover, LCA prevents tumors from releasing substances that cause neighboring cancer cells to grow and proliferate. Prof. Titorenko noted that LCA is the only compound that targets cancer cells, which could translate into tumor-halting power. “This is important for preventing cancer cells from spreading to other parts of the body,” he said, noting that unlike other antiaging compounds, LCA blocks cancer cell growth yet lets normal cells continue to grow.

The next phase for the research team will be to test LCA’s effect on different cancers in mice models. Prof. Titorenko expects that LCA will also kill cancer cells in the research and lead to human clinical trials. “Our study found that LCA kills not only tumors [neuroblastomas], but also human breast cancer cells,” said Prof. Titorenko. “This shows that it has a wide effect on different types of cancers.”

Prof. Titorenko emphasized that dissimilar to agent utilized in chemotherapy, LCA is a natural compound that is already present in humans. Studies have shown that LCA can be safely given to mice by adding it to their food. Therefore, scientists are looking into why LCA is so lethal for cancer cells. Prof. Titorenko conjectures that cancer cells have more sensors for LCA, which makes them more sensitive to the compound than normal cells.

LCA sensors transmit signals to mitochondria. It seems that when these signals are too strong, mitochondria self-destruct and take the cell along with them. Simply stated, Prof. Titorenko and his colleagues engaged in cancer cell disruption by targeting a weakness to LCA.

Related Links:
Concordia University
McGill University
Jewish General Hospital’s Lady Davis Institute



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.